1. Home
  2. LARK vs ENTA Comparison

LARK vs ENTA Comparison

Compare LARK & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LARK
  • ENTA
  • Stock Information
  • Founded
  • LARK 1885
  • ENTA 1995
  • Country
  • LARK United States
  • ENTA United States
  • Employees
  • LARK N/A
  • ENTA N/A
  • Industry
  • LARK Major Banks
  • ENTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • LARK Finance
  • ENTA Health Care
  • Exchange
  • LARK Nasdaq
  • ENTA Nasdaq
  • Market Cap
  • LARK 167.5M
  • ENTA 154.0M
  • IPO Year
  • LARK N/A
  • ENTA 2013
  • Fundamental
  • Price
  • LARK $29.68
  • ENTA $5.33
  • Analyst Decision
  • LARK
  • ENTA Buy
  • Analyst Count
  • LARK 0
  • ENTA 4
  • Target Price
  • LARK N/A
  • ENTA $17.25
  • AVG Volume (30 Days)
  • LARK 31.0K
  • ENTA 203.1K
  • Earning Date
  • LARK 04-30-2025
  • ENTA 05-20-2025
  • Dividend Yield
  • LARK 2.96%
  • ENTA N/A
  • EPS Growth
  • LARK 27.69
  • ENTA N/A
  • EPS
  • LARK 2.59
  • ENTA N/A
  • Revenue
  • LARK $60,798,000.00
  • ENTA $66,590,999.00
  • Revenue This Year
  • LARK N/A
  • ENTA N/A
  • Revenue Next Year
  • LARK N/A
  • ENTA N/A
  • P/E Ratio
  • LARK $11.20
  • ENTA N/A
  • Revenue Growth
  • LARK 9.30
  • ENTA N/A
  • 52 Week Low
  • LARK $17.53
  • ENTA $4.09
  • 52 Week High
  • LARK $31.04
  • ENTA $17.24
  • Technical
  • Relative Strength Index (RSI)
  • LARK 55.52
  • ENTA 48.70
  • Support Level
  • LARK $28.40
  • ENTA $4.96
  • Resistance Level
  • LARK $31.00
  • ENTA $6.23
  • Average True Range (ATR)
  • LARK 1.10
  • ENTA 0.33
  • MACD
  • LARK -0.14
  • ENTA 0.00
  • Stochastic Oscillator
  • LARK 41.75
  • ENTA 37.80

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Share on Social Networks: